TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8422139

Group type: EXPERIMENTAL
Intervention: Fat stitch
Number of subjects: 50

Group type: COMPARATOR
Intervention: No fat stitch
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fat stitch and No fat stitch
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Number of subjects: 50
Study: 2872914

Group type: EXPERIMENTAL
Intervention: Intracapsular extraction and implantation of an iris supported lens (Federov I)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Extracapsular extraction and implantation of an iridocapsular lens (Binkhorst 2‐loop)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Intracapsular extraction and contact lens usage
Number of subjects: 333
Study: 31893302

Group type: EXPERIMENTAL
Intervention: Cold stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sour stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Carbonation stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Neutral stimulation
Number of subjects: 15
Study: 29196825

Group type: EXPERIMENTAL
Intervention: FORTA-guided treatment
Number of subjects: 409

Group type: COMPARATOR
Intervention: Standard geriatric treatment
Number of subjects: 409
Study: 26889737

Group type: EXPERIMENTAL
Intervention: CYD-TDV dengue vaccine
Number of subjects: 23
Study: 24573730

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 120
Study: 22178602

Group type: EXPERIMENTAL
Intervention: New warning labels contradicting positive outcome expectancies
Number of subjects: 0
Study: 20176771

Group type: EXPERIMENTAL
Intervention: 40-minute training sessions, 3 days per week for 7 weeks at 65% of baseline oxygen uptake capacity
Number of subjects: 165

Group type: COMPARATOR
Intervention: 60-minute training sessions, 3 days per week for 7 weeks at 65% of baseline oxygen uptake capacity
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both exercise volumes (40-minute and 60-minute)
Number of subjects: 165
Study: 19132235

Group type: EXPERIMENTAL
Intervention: Self-management group (SMG)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Routine care group (RCG)
Number of subjects: 195
Study: 16190799

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 30
Study: 11929419

Group type: EXPERIMENTAL
Intervention: Decongestants (topical or oral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antihistamines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unknown medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rhinitis group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment effectiveness
Number of subjects: 0
Study: 9466525

Group type: EXPERIMENTAL
Intervention: Investigational vaccines (three types)
Number of subjects: 87
Study: 7892924

Group type: EXPERIMENTAL
Intervention: Preventive services benefit added to Medicare
Number of subjects: 4195

Group type: COMPARATOR
Intervention: Control group (no preventive services benefit)
Number of subjects: 4195
Study: 2705174

Group type: EXPERIMENTAL
Intervention: Hindmarsh operation
Number of subjects: 204

Group type: COMPARATOR
Intervention: Bassini operation
Number of subjects: 204
Study: 822964

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (DSCG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30907934

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 29025227

Group type: EXPERIMENTAL
Intervention: Vibration anesthesia
Number of subjects: 25

Group type: COMPARATOR
Intervention: No vibration
Number of subjects: 25
Study: 26602106

Group type: EXPERIMENTAL
Intervention: Intravaginal culture device (IVC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 10
Study: 23153423

Group type: EXPERIMENTAL
Intervention: Primary balloon angioplasty (PBA) of a long segment of the cephalic vein from the wrist up to the elbow (n=19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrostatic dilatation (HD) of a short venous segment (5 cm) at the level of the anastomosis (n=21)
Number of subjects: 40
Study: 21299861

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19564680

Group type: EXPERIMENTAL
Intervention: Direct cellular communication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Indirect page communication
Number of subjects: 60
Study: 17010462

Group type: EXPERIMENTAL
Intervention: 1.5mg/kg caffeine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3.0mg/kg caffeine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4.5mg/kg caffeine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0mg/kg (placebo)
Number of subjects: 20
Study: 12762972

Group type: EXPERIMENTAL
Intervention: Lifestyle modifications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other interventions
Number of subjects: 0
Study: 17224217

Group type: EXPERIMENTAL
Intervention: 60microg YIC immunization
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alum (control)
Number of subjects: 20
Study: 10899491

Group type: EXPERIMENTAL
Intervention: Clonidine HCl (2 microg/kg of body weight)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8895283

Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine 0.5 micrograms/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 80
Study: 1803847

Group type: EXPERIMENTAL
Intervention: Active buffering lozenge (Profylin)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo lozenge (not buffered)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Active buffering lozenge (Profylin) after sucrose rinse
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo lozenge after sucrose rinse
Number of subjects: 33
Study: 6671105

Group type: EXPERIMENTAL
Intervention: Veridical auditory biofeedback
Number of subjects: 4

Group type: COMPARATOR
Intervention: Auditory pseudofeedback (random signal)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Auditory pseudofeedback (gradually increasing frequency)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Auditory pseudofeedback (gradually decreasing frequency)
Number of subjects: 4
Study: 31119846

Group type: EXPERIMENTAL
Intervention: TRK‐100STP 120 μg
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: TRK‐100STP 240 μg
Number of subjects: 892

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 892
Study: 28273240

Group type: EXPERIMENTAL
Intervention: Laser pan-retinal photocoagulation with intravitreal bevacizumab injections
Number of subjects: 19

Group type: COMPARATOR
Intervention: Laser pan-retinal photocoagulation alone
Number of subjects: 19
Study: 26649465

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy (ICBT) with therapist support for 10 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 93
Study: 24385269

Group type: EXPERIMENTAL
Intervention: Structured care program (SMART group)
Number of subjects: 2717

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 2717
Study: 22323279

Group type: EXPERIMENTAL
Intervention: Intervention condition (integrating physical activity and nutrition practices into workplace routine during non-discretionary paid work time)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intervention condition
Number of subjects: 15
Study: 21059433

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 228
Study: 17973984

Group type: EXPERIMENTAL
Intervention: Manual acupuncture at LI4, ST36 and LV3
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tactile stimulation (sensory control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LI4 acupuncture point
Number of subjects: 42
Study: 15983390

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 12476542

Group type: EXPERIMENTAL
Intervention: Desloratadine/pseudoephedrine (5 mg/240 mg)
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Desloratadine (5 mg)
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Pseudoephedrine (240 mg)
Number of subjects: 1018
Study: 9761434

Group type: EXPERIMENTAL
Intervention: UFT (Tegafur and Uracil) administered post-operatively to 98 patients
Number of subjects: 655

Group type: COMPARATOR
Intervention: Control group (no UFT administered to 557 patients)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: UFT for p-stage I disease
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: UFT for p-stage IIIa, pN2 disease
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: UFT efficacy in multivariate analysis
Number of subjects: 655
Study: 7642053

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy (thrombolysis) for AMI
Number of subjects: 8025
Study: 2767019

Group type: EXPERIMENTAL
Intervention: Meter-plus-contract
Number of subjects: 72

Group type: COMPARATOR
Intervention: Meter-alone
Number of subjects: 72
Study: 31074161

Group type: EXPERIMENTAL
Intervention: Restylane Lyft
Number of subjects: 100

Group type: COMPARATOR
Intervention: Restylane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Restylane Lyft and Restylane
Number of subjects: 100
Study: 28329389

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 8404

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 8404
Study: 26337626

Group type: EXPERIMENTAL
Intervention: Progressive multicomponent intervention (home-based progressive strength, mobility and activities of daily living training)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care rehabilitation (control group)
Number of subjects: 22
Study: 24398761

Group type: EXPERIMENTAL
Intervention: n-hexyl-α-cyanoacrylate glue
Number of subjects: 208

Group type: COMPARATOR
Intervention: Prolene sutures
Number of subjects: 208

Group type: COMPARATOR
Intervention: Tackers
Number of subjects: 208
Study: 22003058

Group type: EXPERIMENTAL
Intervention: Cooling via a water-perfused suit
Number of subjects: 21
Study: 19665606

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 clade 1 subunit vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plain H5N1 clade 1 subunit vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pseudoparticle neutralization (PPN) assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hemagglutination inhibition (HI) assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viral micro‐neutralization (MN) assay
Number of subjects: 0
Study: 17659909

Group type: EXPERIMENTAL
Intervention: High-protein diet (2.0 g protein/kg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-protein diet (0.5 g protein/kg/day)
Number of subjects: 22
Study: 16220761

Group type: EXPERIMENTAL
Intervention: Fibrin gel
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fibrin sheet
Number of subjects: 91
Study: 11895913

Group type: EXPERIMENTAL
Intervention: Docetaxel (D)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Sequential methotrexate and 5‐fluorouracil (MF)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Low bcl‐2 expression
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: High fasL expression
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: bcl‐2
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: fasL
Number of subjects: 283
Study: 10362116

Group type: EXPERIMENTAL
Intervention: Melatonin 40 mg orally for 21 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7719395

Group type: EXPERIMENTAL
Intervention: Weight loss of 4.5 kg or more from baseline to 6 months (mean weight loss of 11.8 kg or 13% of initial body weight)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 159
Study: 1788754

Group type: EXPERIMENTAL
Intervention: Intravenous PGE1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous Pentoxifylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training group (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentoxifylline group (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PGE1 group (control)
Number of subjects: 0
Study: 7259364

Group type: EXPERIMENTAL
Intervention: Propranolol (30 microgram/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Acebutolol (150 microgram/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (isotonic glucose solution)
Number of subjects: 5
Study: 31653513

Group type: EXPERIMENTAL
Intervention: anti-PCSK9 monoclonal antibodies (mAbs) alirocumab or evolocumab
Number of subjects: 24
Study: 30152298

Group type: EXPERIMENTAL
Intervention: Supported 6-week online intervention based on cognitive behavioural therapy (iCBT)
Number of subjects: 36
Study: 28706174

Group type: EXPERIMENTAL
Intervention: Motivational interviewing program (8 sessions, 60 minutes each, once a week)
Number of subjects: 62
Study: 25698197

Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 μg/kg) administered intravenously during re-warming
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (saline administered intravenously during re-warming)
Number of subjects: 102
Study: 23365113

Group type: EXPERIMENTAL
Intervention: Daikenchuto (TJ-100)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 21896879

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg/d
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 19808125

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 1674

Group type: COMPARATOR
Intervention: Biphasic human insulin 30 (BHI 30)
Number of subjects: 1674

Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 1674

Group type: COMPARATOR
Intervention: BHI 30
Number of subjects: 1674
Study: 17343130

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 4360

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 4360

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 4360

Group type: COMPARATOR
Intervention: Rosiglitazone vs Metformin
Number of subjects: 4360

Group type: COMPARATOR
Intervention: Rosiglitazone vs Glibenclamide
Number of subjects: 4360
Study: 15670436

Group type: EXPERIMENTAL
Intervention: Population-based disease management and case management
Number of subjects: 8504

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8504
Study: 11839457

Group type: EXPERIMENTAL
Intervention: Alcoholic red wine (3 glasses, consumed 1 hour apart)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo red wine (3 glasses, consumed 1 hour apart)
Number of subjects: 0
Study: 9737646

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.3 mg
Number of subjects: 751

Group type: COMPARATOR
Intervention: Gemfibrozil 1200 mg
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Cerivastatin and Gemfibrozil
Number of subjects: 751
Study: 3071952

Group type: EXPERIMENTAL
Intervention: Orchiectomy plus Anandron (300 mg daily)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Orchiectomy plus placebo
Number of subjects: 98
Study: 29293181

Group type: EXPERIMENTAL
Intervention: Intermittent boluses (21 mL/3 h) of 0.2% ropivacaine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Continuous infusion (7 mL/h) of 0.2% ropivacaine
Number of subjects: 110
Study: 27669730

Group type: EXPERIMENTAL
Intervention: ATG+G-CSF
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 24070164

Group type: EXPERIMENTAL
Intervention: FOLFOX-4 regimen (oxaliplatin 85 mg/m², leucovorin 200 mg/m², 5-FU bolus 400 mg/m², 5-FU infusion 600 mg/m²) administered every 2 weeks for two consecutive days.
Number of subjects: 37
Study: 22552314

Group type: EXPERIMENTAL
Intervention: Patellar denervation by electrocautery
Number of subjects: 35

Group type: COMPARATOR
Intervention: Debridement alone (control)
Number of subjects: 35
Study: 19940093

Group type: COMPARATOR
Intervention: Flavored placebo with no electrolytes (P)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Placebo with electrolytes (P + E)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3% carbohydrate solution with electrolytes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate solution with electrolytes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 12% carbohydrate solution with electrolytes
Number of subjects: 15
Study: 19018917

Group type: EXPERIMENTAL
Intervention: Clinical-organizational integrated audits with feedback and presence of facilitators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard observation
Number of subjects: 0
Study: 15813841

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication therapy
Number of subjects: 226
Study: 12020181

Group type: EXPERIMENTAL
Intervention: Symptom-triggered treatment with oxazepam
Number of subjects: 117

Group type: COMPARATOR
Intervention: Fixed-schedule treatment with oxazepam
Number of subjects: 117
Study: 10219832

Group type: EXPERIMENTAL
Intervention: Plastic flakes (24 g/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Small granules (24 g/day)
Number of subjects: 18
Study: 8751016

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2145400

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg IV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7206593

Group type: EXPERIMENTAL
Intervention: diatrizoate (Urografin 76%) alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: diatrizoate with added calcium (11.3 mmol/l)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: metrizamide (Amipaque)
Number of subjects: 15

Group type: COMPARATOR
Intervention: diatrizoate
Number of subjects: 15
Study: 31651690

Group type: EXPERIMENTAL
Intervention: Unmarried status
Number of subjects: 5707

Group type: EXPERIMENTAL
Intervention: Unmarried status adjusted for traditional cardiovascular risk factors
Number of subjects: 5707

Group type: EXPERIMENTAL
Intervention: Unmarried status adjusted for coronary calcium score
Number of subjects: 5707
Study: 30522969

Group type: EXPERIMENTAL
Intervention: ibrutinib plus obinutuzumab
Number of subjects: 229

Group type: COMPARATOR
Intervention: chlorambucil plus obinutuzumab
Number of subjects: 229
Study: 27789095

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg twice a day (BID) for 4 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Aspirin and Lovenox in conjunction with pneumatic compression devices (from a recent randomized controlled trial)
Number of subjects: 112
Study: 26718672

Group type: EXPERIMENTAL
Intervention: Percutaneous repair with MitraClip device
Number of subjects: 258

Group type: COMPARATOR
Intervention: Conventional MV surgery
Number of subjects: 258
Study: 23244709

Group type: EXPERIMENTAL
Intervention: Cetuximab combined with CAPIRI or CAPOX
Number of subjects: 121
Study: 21099675

Group type: EXPERIMENTAL
Intervention: Web-based diabetes education (n = 61)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (n = 61)
Number of subjects: 122
Study: 18848401

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 16709212

Group type: EXPERIMENTAL
Intervention: Decision-aid leaflet
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control leaflet
Number of subjects: 328
Study: 15646218

Group type: EXPERIMENTAL
Intervention: Duraphat varnish
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cavity Shield varnish
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Duraflor varnish
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fluor Protector varnish
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no varnish)
Number of subjects: 75
Study: 11417442

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg once daily
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg once daily
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg once daily
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg four times daily
Number of subjects: 33
Study: 9924266

Group type: EXPERIMENTAL
Intervention: Lutein supplementation (15 mg/d as mixed ester forms) for 4 months
Number of subjects: 18
Study: 8313548

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3372884

Group type: EXPERIMENTAL
Intervention: Birmingham accent
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Yorkshire accent
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: South east educated accent
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Asian accented English
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (south east educated accent)
Number of subjects: 72
Study: 30224533

Group type: EXPERIMENTAL
Intervention: Oral rifampin 10 mg/kg (450 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral rifampin 20 mg/kg (900 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral rifampin 30 mg/kg (1,350 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral rifampin (all doses)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard dose of rifampin
Number of subjects: 60
Study: 26873163

Group type: EXPERIMENTAL
Intervention: Patient education information pamphlets
Number of subjects: 49

Group type: COMPARATOR
Intervention: Verbal consent only
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pre-op HADS score
Number of subjects: 49
Study: 25626851

Group type: EXPERIMENTAL
Intervention: Lateral wedge insole with subtalar strapping
Number of subjects: 58

Group type: COMPARATOR
Intervention: Neutral insole with subtalar strapping (Control)
Number of subjects: 58